Zacks Investment Research
14 Jul 2026, 15:46 UTC · 2h ago
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
14 Jul 2026, 15:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
BioMarin expects Voxzogo to generate between $0.98 billion and $1.03 billion in sales in 2026. — Provides a concrete, high-value revenue target that anchors the company's near-term valuation.
+0.60BioMarin expects to submit a regulatory filing in Q3 2026 for a second indication (hypochondroplasia) following positive Phase III data. — A successful label expansion significantly increases the addressable market and long-term growth potential.
+0.50Ascendis Pharma's Yuviwel received FDA approval in February 2026, creating the first direct competitor to Voxzogo. — Direct competition in a specialized market threatens BioMarin's pricing power and market share.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
The FDA has accepted BioMarin's application to convert Voxzogo's accelerated approval to full traditional approval, with a decision expected Feb 28, 2027. — Full approval reduces regulatory risk and solidifies market positioning, though the decision is far in the future.
Which stocks this story touches
The FDA accepted its sNDA for full approval of Voxzogo and the company reported positive Phase III data for a second indication.
The company's product Yuviwel is identified as a direct competitor that increases competition in the achondroplasia market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
6h ago
